Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 43Waldenstrom Macroglobulinemia 4Recurrence 4Lymphoma, Mantle-Cell 3Lymphoma 3Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Smoldering Multiple Myeloma 1Sarcoma, Kaposi 1Plasmacytoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Hematologic Diseases 1Graft vs Host Disease 1Genetic Diseases, Inborn 1Congenital Abnormalities 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 59Dexamethasone 56Melphalan 48Peripheral Blood Stem Cell Transplantation 37Busulfan 34Bortezomib 32fludarabine phosphate 29Lenalidomide 27Filgrastim 27Tacrolimus 24Antilymphocyte Serum 24Thalidomide 22Mycophenolic Acid 22Radiotherapy 21Methotrexate 15Cyclosporine 15Etoposide 14sargramostim 13Granulocyte Colony-Stimulating Factor 11Whole-Body Irradiation 10Methylprednisolone 10Interferon-alpha 10fludarabine 9daratumumab 9Carmustine 9carfilzomib 7Rituximab 7Prednisone 7Cytarabine 7Cord Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Plasma Cell × ixazomib × Clear all
NCT04052880 2025-07-20

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

Icahn School of Medicine at Mount Sinai

Phase 2 Active not recruiting
17 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡